| Thromboembolism |
0 |
1 |
| Antithrombotics |
0 |
1 |
| Atrial Fibrillation |
0 |
0.44 |
| Endoscopy |
0 |
1 |
| Anticoagulation Therapy |
0 |
1 |
| Clinical Guidelines |
0 |
0.34 |
| Cardiovascular Risk Management |
0 |
0.85 |
| Deep Venous Thrombosis |
0 |
0.22 |
| Hemorrhage |
0 |
0.22 |
| Cerebrovascular Accident |
0 |
0.2 |
| Hypertension |
0 |
0.2 |
| Gastrointestinal Hemorrhage |
0 |
0.19 |
| Coronary Artery Disease (CAD) |
0 |
0.18 |
| Receptors |
0 |
0.17 |
| Heart Failure (HF) |
0 |
0.16 |
| Heart |
0 |
0.14 |
| Stent |
0 |
0.13 |
| Drug-Eluting Stent |
0 |
0.11 |
| Valvular Heart Disease |
0 |
0.11 |
| Biliary Stent |
0 |
0.1 |
| Bowel Preparation |
0 |
0.1 |
| Coronary Stent |
0 |
0.1 |
| Peripheral Artery Disease |
0 |
0.09 |
| Colonoscopy |
0 |
0.08 |
| Perioperative Care |
0 |
0.08 |
| Thrombosis |
0 |
0.08 |
| Pain Management |
0 |
0.07 |
| Renal Failure |
0 |
0.07 |
| Polyp |
0 |
0.06 |
| Antiplatelet Agent |
0 |
0.05 |
| Artery |
0 |
0.05 |
| Aspirin |
0 |
0.05 |
| Biliary Disease |
0 |
0.05 |
| Platelet Count |
0 |
0.05 |
| Thorax |
0 |
0.05 |
| Direct Factor Xa Inhibitor |
0 |
0.04 |
| Low-Molecular-Weight Heparin |
0 |
0.04 |
| Thrombin Inhibitor |
0 |
0.04 |
| Acute Coronary Syndrome |
0 |
0.03 |
| Biopsy |
0 |
0.03 |
| Europe |
0 |
0.03 |
| Factor II |
0 |
0.03 |
| Hand |
0 |
0.03 |
| Internship |
0 |
0.03 |
| Myocardial Infarction (MI) |
0 |
0.03 |
| Transient Ischemic Attack |
0 |
0.03 |
| Unfractionated Heparin |
0 |
0.03 |
| Venous Thromboembolism (VTE) |
0 |
0.03 |
| Appendix |
0 |
0.02 |
| Cerebrovascular Disease |
0 |
0.02 |
| Diabetes Mellitus |
0 |
0.02 |
| ERCP |
0 |
0.02 |
| Fellowship |
0 |
0.02 |
| Infarction |
0 |
0.02 |
| Intravenous |
0 |
0.02 |
| Mitral Valve |
0 |
0.02 |
| Nonsteroidal Anti-Inflammatory Agents |
0 |
0.02 |
| Percutaneous Coronary Intervention |
0 |
0.02 |
| Postoperative |
0 |
0.02 |
| Prophylaxis |
0 |
0.02 |
| Proteases |
0 |
0.02 |
| Resection |
0 |
0.02 |
| Shared Decision-Making |
0 |
0.02 |
| Thrombus |
0 |
0.02 |
| Vitamin |
0 |
0.02 |